### PATENT COOPERATION TREATY

## **PCT**

REC'D 18 JAN 2005

PCT

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International				
R2554-PCT		Preliminary Examination Report (Form PCT/IPEA/416)				
International application No. PCT/EP 03/10715	International filing date (day/monti 24.09.2003	h/year) Priority date (day/month/year) 30.09.2002				
International Patent Classification (IPC) or bo A61K9/00	th national classification and IPC					
Applicant UNIVERSITEIT GENT et al.						
This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.						
2. This REPORT consists of a total of	2. This REPORT consists of a total of 4 sheets, including this cover sheet.					
been amended and are the t	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).					
These annexes consist of a total o	These annexes consist of a total of 1 sheets.					
This report contains indications rel	ating to the following items:					
	ating to the following items.	•				
I ⊠ Basis of the opinion II □ Priority						
		ventive step and industrial applicability				
V 🛛 Reasoned statement u						
VI   Certain documents cite	-					
	nternational application					
	n the international application	•				
The state of the international application						
Date of submission of the demand	Date of c	completion of this report				
16.04.2004		2005				
Name and mailing address of the international preliminary examining authority:	d Authoriz	ed Officer				
European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465		iva, A				

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/10715

<ol> <li>Basis of the repo</li> </ol>	rl	מ	rei	the	of	3asis	I.
---------------------------------------	----	---	-----	-----	----	-------	----

1. With regard to the **elements** of the international application (Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)):

	De	Description, Pages				
	1-2	7	as originally filed			
Claims, Numbers						
	6-1	8	as originally filed			
	1-5		received on 03.05.2004 with letter of 03.05.2004			
	Dra	wings, Sheets				
	1/4-	-4/4	as originally filed			
<ol><li>With regard to the language, all the elements marked above were available or furnished to this Auth- language in which the international application was filed, unless otherwise indicated under this item.</li></ol>						
	The	hese elements were available or furnished to this Authority in the following language: , which is:				
		the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).				
		the language of a tra Rule 55.2 and/or 55.	anslation furnished for the purposes of international preliminary examination (under .3).			
<ol> <li>With regard to any nucleotide and/or amino acid sequence disclosed in the international applica international preliminary examination was carried out on the basis of the sequence listing: ,</li> </ol>						
		contained in the international application in written form.				
		filed together with the international application in computer readable form.				
		furnished subsequently to this Authority in written form.				
		furnished subsequently to this Authority in computer readable form.				
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.				
		The statement that t listing has been furn	he information recorded in computer readable form is identical to the written sequence ished.			
4. The amendments have resulted in the cancellation of:						
		the description,	pages:			
		the claims,	Nos.:			
		the drawings,	sheets:			

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/EP 03/10715

5. 🗆	This report has been established as if (some of) the amendments had not been made, since they have
	been considered to go beyond the disclosure as filed (Rule 70.2(c)).

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-18

No: Claims

Inventive step (IS) Yes: Claims 1-18

No: Claims

Industrial applicability (IA) Yes: Claims 1-18

No: Claims

2. Citations and explanations

see separate sheet

### Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1 WO 99/63971 A , disclosing preparations with a microosmotic core, optionally coated for the controlled delivery of drugs.
- D2 WO 99/51208 A, diclosing a matrix with controlled erosion
- D3 WO 89/09066 A, disclosing preparations comprising a matrix with controlled erosion, optionally coated
- D4 US 5 213 808 A , disclosing multilayered pharmaceutical forms with a matrix and surfactant;
- D5 WO 01/05376 A, disclosing felodipine pharmaceutical forms with a matrix and a "solubilizer"

Unless otherwise indicated, reference is made to the relevant passages emphasized in the International Search Report.

In several of the cited prior art items (D1, D2, D6), preparations with the same or a very similar structure structure and the same ingredients are disclosed. They also can be optionally coated. However, in all cases, the hydrophilic cellulose polymer is present in the core in a quantity which is greater than that of the amphiphilic material.

Therefore novelty is acknowledged to the present set of claims. In view of the good in vitro and in vivo results, the presence of an inventive step can be acknowledged as well. In summary, present claims 1-18 appear to comply with the requirements of the PCT as far as novelty, inventivity and industrial applicability are concerned.

#### **CLAIMS**

- 1. A biologically active composite solid shaped article comprising an outer layer and an inner core, wherein:
  - (a) the outer layer is an extrudable coating retaining the structural integrity of the inner core and consisting of :
  - at least one polymeric component selected from the group consisting of hydrophobic cellulose polymers, acrylate (co)polymers, polyvinyl-pyrrolidone, polyethylene oxide, polyvinyl alcohol, poly(ethylene-co-vinyl acetate), and
  - optionally at least one plasticizer for the said polymeric component,
  - (b) the inner core fills said outer layer and comprises:
  - at least a biologically active ingredient, and
  - an excipient for the said biologically active ingredient, said excipient comprising at least one hydrophilic cellulose polymer and an amphiphilic material, wherein the weight ratio of said hydrophilic cellulose polymer to said amphiphilic material is from 0.2:1 to 0.6:1.
- 2. A biologically active composite solid shaped article according to claim 1, wherein the hydrophilic cellulose polymer of the inner core is a hydroxyalkylalkylcellulose.
- 3. A biologically active composite solid shaped article according to claim 1 or claim 2, wherein the hydrophilic cellulose polymer of the inner core is hydroxypropylmethylcellulose.
- 4. A biologically active composite solid shaped article according to any of claims 1 to 3, wherein the amphiphilic material of the inner core has both a portion derived from a glyceride and a portion derived from a polyethylene glycol ester.
- 5. A biologically active composite solid shaped article according to any of claims 1 to 4, wherein the weight ratio of the hydrophilic cellulose polymer to the amphiphilic material in the blend of the inner core is from 0.3:1 to 0.6:1.

4

5

10

. 15

20

25

#### Sheet No. ..1....

Box No. VIII (iv) DECLARATION: INVENTORSHIP (only for the purposes of the designation of the United States of America)
The declaration must conform to the following standardized wording provided for in Section 214; see Notes to Boxes Nos. VIII, VIII (i) to (v) (in general) and the specific Notes to Box No.VIII (iv). If this Box is not used, this sheet should not be included in the request.

### Declaration of inventorship (Rules 4.17(iv) and 51bis.1(a)(iv)) for the purposes of the designation of the United States of America:

I hereby declare that I believe I am the original, first and sole (if only one inventor is listed below) or joint (if more than one inventor is listed below) inventor of the subject matter which is claimed and for which a patent is sought.

This declaration is directed to the international application of which it forms a part (if filing declaration with application).

This declaration is directed to international application No. PCT/EP.O.3 /. 107.1.5....... (if furnishing declaration pursuant to Rule 26ter).

I hereby declare that my residence, mailing address, and citizenship are as stated next to my name.

I hereby state that I have reviewed and understand the contents of the above-identified international application, including the claims of said application. I have identified in the request of said application, in compliance with PCT Rule 4.10, any claim to foreign priority, and I have identified below, under the heading "Prior Applications," by application number, country or Member of the World Trade Organization, day, month and year of filing, any application for a patent or inventor's certificate filed in a country other than the United States of America, including any PCT international application designating at least one country other than the United States of America, having a filing date before that of the application on which foreign priority is claimed.

I hereby acknowledge the duty to disclose information that is known by me to be material to patentability as defined by
37 C.F.R. § 1.56, including for continuation-in-part applications, material information which became available between the filing date
of the prior application and the PCT international filing date of the continuation-in-part application.

Prior Applications: .GB.0222612.4....

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name: Jean Paul Remon	
Residence: Melle, Belgium (city and either US state, if applicable, or country)	
. Variable at 4.4	
R-9000 Mallaft	•••••
Citizenship: Belgian	
Inventor's Signature:  (if not contained in the request, or if declaration is corrected or added under Rule 26ter safer the filing of the international application. The signature must be that of the inventor, not that of the agent)	Date: Ottobre 17th Load (of signature which is not contained in the request, or of the declaration that is corrected or added under Rule 26ter after the filing of the international application)
Name: Els Mehuys	
Residence: StDenijs Westrem, Belgium (city and either US state. if applicable, or country)	
Mailing Address: Putkapelstraat 47	
B-9051 St -Deniis Westrem	••••
Citizenship: Belgian	
Inventor's Signature:  (if not contained in the edgest or if declaration is concerted or added under Rule 26th after the filing of the international application. The signature must be that of the inventor, not that of the agent)	Date: Octobal

This declaration is continued on the following sheet, "Continuation of Box No. VIII (iv)".

Sheet No.: ... 2...

Continuation of Box No. VIII (i) to (v) DECLARATION  If the space is insufficient in any of Boxes Nos. VIII (i) to (v) to furnish all the information, including in the case where more than two inventors are to be named in Box No. VIII (iv), in such case, write "Continuation of Box No. VIII" (indicate the item number of the Box) and furnish the information in the same manner as required for the purposes of the Box in which the space was insufficient. If additional space is needed in respect of two or more declarations, a separate continuation box must be used for each such declaration. If this Box is not used, this sheet should not be included in the request.			
Continuation of Box No. VIII (iv):			
Name: Chris Vervaet			
(city and either US state, if applicable, or country)			
Mailing Address: Pieter Pruimstraat 11  B-8870 Izegem	•••••••••••••••••••••••••••••••••••••••		
Citizenship: Belgian	•••••		
Inventor's Signature: (if not contained in the request, or if declaration is corrected or added under Rule 26ter after the filing of the international application. The signature must be that of the inventor, not that of the agent)	Date:		
•			
	1		
	•		
	e:		
: .			
•			
	•		